Oncology

Clinical Study

A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung Cancer

Kosmas C.a · Tsavaris N.b · Koutras A.c · Makatsoris T.c · Mylonakis N.a · Tzelepis G.b · Dimitrakopoulos A.b · Spyropoulos K.b · Polyzos A.b · Karabelis A.a · Kalofonos H.P.c

Author affiliations

aDepartment of Medicine, Second Division of Medical Oncology, ‘Metaxa’ Memorial Hospital, Piraeus, bMedical Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, Athens, and cDepartment of Medicine/Oncology/Pulmonary Medicine, Patras University School of Medicine, Rio, Patras, Greece

Keywords: DocetaxelIfosfamideCarboplatinNon-small-cell lung cancer

Related Articles for ""
Oncology 2005;69:333–341
https://doi.org/10.1159/000089681

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: March 14, 2005
Accepted: June 19, 2005
Published online: December 05, 2005
Issue release date: November 2005

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Purpose: In the present phase II study we evaluated the docetaxel-ifosfamide-carboplatin (DICb) combination in the outpatient setting in patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with advanced NSCLC (stages IIIB/IV), WHO performance status (PS) <2, and no prior chemotherapy were eligible. Chemotherapy drug doses were: docetaxel: 80 mg/m2, ifosfamide: 3.5 g/m2, and carboplatin at a target area under the curve of 5 (based on Calvert’s formula), all on day 1, followed by prophylactic G-CSF. Results: Fourty patients were entered and all are evaluable for response and toxicity: median age: 64 (48–72); PS: 1 (0–1); gender: 29 males/11 females; stages: IIIB: 13 (33%), IV: 27 (67%). Metastatic sites at diagnosis included: lymph nodes: 25; bone: 7; liver: 4; brain: 5; lung nodules: 13; adrenals: 6. Responses were as follows: 22/40 [55%; 95% confidence interval (CI), 54–81%] evaluable patients responded: 4 complete responses, 18 partial responses, 11 had stable disease, and 7 had progressive disease. The median response duration was 7 months (range 2–14 months), median time to progression 9 months (range 2–18 months) and median overall survival 11 months (range 3–46+ months). 1-year survival was 47.5%. Grade 3/4 toxicities included: neutropenia 28/40, with 12 developing grade 4 and 12% febrile neutropenia, thrombocytopenia grade 3: 3/40 and grade 4: 1/40, no grade 3 neuropathy, grade 1 CNS toxicity in 3, no renal toxicity, 8 grade 2 diarrhea and 4 grade 3 vomiting. Conclusion: In the present phase II study the DICb combination yielded important activity and good tolerability in advanced NSCLC.

© 2005 S. Karger AG, Basel



Related Articles:

References

  1. Non-small cell lung cancer cooperative group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patient data from 52 randomised clinical trials. Br Med J 1995;311:899–909.
  2. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602–1613.
    External Resources
  3. Ettinger DS: Ifosfamide in the treatment of non-small cell lung cancer. Semin Oncol 1989(suppl 3);16:31–38.
  4. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM: Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988;58:359–361.
    External Resources
  5. Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Meacci M, Corgna E, Darwish S, Scarcella L, Santucci A, Ballatori E, Tonato M: Chemotherapy of advanced non-small cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1995;6:347–353.
    External Resources
  6. Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M, Klastersky J: European Lung Cancer Working Party. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002;13:874–882.
    External Resources
  7. Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP: A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Int J Cancer 2002;98:141–147.
    External Resources
  8. Zaniboni A, Meriggi F, Rizzi A, Alghisi A, Pascarella A, Bozzola G, Mutti S, Marini G: Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer. Semin Oncol 1997;24(suppl 12):70–72.
  9. Gandara DR, Vokes E, Green M, Bonomi P, DeVore R, Comis R, Carbone D, Karp D, Belani C: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000;18:131–135.
    External Resources
  10. Tsavaris N, Polyzos A, Kosmas C, Giannikos L, Gogas J: A feasibility study of one-hour paclitaxel infusion in solid tumors. Cancer Chemother Pharmacol 1997;40:353–357.
    External Resources
  11. Tsavaris N, Fountzilas G, Mylonakis N, Athanassiadis A, Kosmas C, Karakousis C, Bacoyiannis C, Kosmidis P: A randomized comparative study of antiemetic prophylaxis with ondansetron in a single 32 mg loading dose vs. 8 mg every six hours, in patients under cisplatin-based chemotherapy. Oncology 1998;55:513–516.
    External Resources
  12. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM: Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale. Eur J Cancer 1993;29A(suppl 1):51–58.
    External Resources
  13. Cox DR: The analysis of binary data. London, Methuen, 1970.
  14. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457–481.
    External Resources
  15. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
    External Resources
  16. Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–2103.
    External Resources
  17. Fossella FV, De Vore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354–2362.
    External Resources
  18. Belani CP, Einzig A, Bonomi P, Dobbs T, Capozzoli MJ, Earhart R, Cohen LJ, Luketich JD: Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000;11:673–678.
    External Resources
  19. Giannakakis T, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V: A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res 2002;22:3743–3748.
    External Resources
  20. Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, Wong J, McNeil E, Bishop JF: Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14:449–454.
    External Resources
  21. Jahanzeb M, Sarna G, Hirsch R, Radice P, Koletsky A, Martinez M, Kruglyak E, Wolin E, Camacho E, Kronish L, Motl S: Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res 2004;24:1239–1242.
    External Resources
  22. Ramalingam S, Dobbs TW, Einzig AI, Wojtowicz-Praga S, Cascino M, Bonomi P, Belani CP: Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemother Pharmacol 2004;53:439–444.
    External Resources
  23. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016–3024.
    External Resources
  24. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 1993;15:83–88.
    External Resources
  25. Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN: A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 1998;82:561–566.
    External Resources
  26. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 1993;11:2010–2020.
    External Resources
  27. Lind MJ, McGowan AT, Hadfield JA, Thatcher N, Crowther D, Fox BW: The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 1989;38:1835–1840.
    External Resources
  28. Diaz J, Andreu J: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere. Biochemistry 1993;32:2747–2755.
    External Resources
  29. Haldar S, Basu A, Croce C: Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229–233.
    External Resources
  30. Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, Van Meerbeek J, Wanders J, Franklin HR, Kaye S: Taxotere is an active drug in non small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994;70:384–387.
    External Resources
  31. Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Wooley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232–1237.
    External Resources
  32. Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KMW, Venkatraman ES, Woolley K, Heelan RT, Kris MG: Phase II trial of a 75 mg/m2 dose of docetaxel given with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968–972.
    External Resources
  33. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:1238–1244.
    External Resources
  34. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M: Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 1995;22(suppl 6):90–96.
    External Resources
  35. Kosmas C, Tsavaris N, Polyzos A, Malamos NA, Katsikas M, Antonopoulos MJ: Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br J Cancer 2000;82:300–307.
    External Resources
  36. Kosmas C, Tsavaris N, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ: A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer. Cancer 2000;89:774–782.
    External Resources
  37. Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C: A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001;19:119–126.
    External Resources
  38. Giannakakis T, Ziras N, Kakolyris S, Mavroudis D, Androulakis N, Agelaki S, Parashos M, Sarra E, Dimou T, Hatzidaki D, Vlachonikolis J, Georgoulias V: Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: A multicentre phase I study. Eur J Cancer 2000;36:742–747.
    External Resources
  39. Kasahara K, Myo S, Iwasa K, Kimura H, Shirasaki H, Yasuda U, Shibata K, Shintani H, Nishi K, Fujimura M, Nakao S: A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method. Jpn J Clin Oncol 2002;32:512–516.
    External Resources
  40. Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G: Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small cell lung cancer: a phase I-II study. J Clin Oncol 1999;17:2316–2325.
    External Resources
  41. Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldis G, Maiorino L, Bilancia D, Nicolella G, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco A, Comella G: Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small cell lung cancer: A phase II study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999;17:1526–1534.
    External Resources
  42. Crown JP, Donnellan P, O’Sullivan C, Rowan S, Jones M, Chan KM, Duffy K, O’Leary V, Breathnach O, Moulton BC, MacErlean D, Schrance M, Murray R, Nutty S, Flynn C, Fennelly D, Moriarty M, O’Neill S, Lynch V, Nicholas WM, Gallagher C, Armstrong J: Phase I/II evaluation of escalating dose docetaxel, ifosfamide and cisplatin with lenograstim support, in patients with stage III/IV non-small cell lung cancer (abstract 1840): An Irish Clinical Oncology Research Group (ICORG) Study. Proc Am Soc Clin Oncol 1999;18:477a.
  43. Mauer AM, Ansari RH, Hoffman PC, Krauss SA, Taber D, Tembe SA, Gabrys GT, Cotter T, Schumm LP, Szeto L, Vokes EE: Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer. Ann Oncol 2003;14:722–728.
    External Resources
  44. Boni C, Zanelli F: Ifosfamide in non-small cell lung cancer. Oncology 2003;65(suppl 2):50–54.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: March 14, 2005
Accepted: June 19, 2005
Published online: December 05, 2005
Issue release date: November 2005

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2005, Vol.69, No. 4

November 2005

Article

Recommend This
TOP